“If I could describe INOVOTION in one sentence,” says Olivier Baverey, INOVOTION’s US representative; “it would be accelerating research in oncology, while minimizing costs and risk.”
INOVOTION began operations in 2014, after 5 years of R&D and more than 150 studies based in Grenoble, France. The company’s founder, Professor Jean Viallet, developed their technology at the Institute for Advanced Biosciences, a cancer research center at Grenoble Alpes University. They have produced a highly sensitive and easily reproducible assay for preclinical anticancer drug discovery program based on a chicken embryo model. Its basis lies in monitoring the growth and the metastatic dissemination of human tumor cells.
The company’s tagline is “which molecule will stand out?” It refers to one common use for their technology, which involves screening compounds in a library of assets. INOVOTION’s technology acts as an intermediate in vivo step in the drug discovery process, between in vitro testing and classical preclinical assays on mice. It improves the efficiency of the drug discovery process, as demonstrated by several studies published at the commercialization of their launch.
“Companies need to get funds for research, and most of the time, investors like to see in vivo data,” says Baverey. “Our products end up raising funds for animal testing.”
INOVOTION is looking to increase their commercial presence. As of August, 2018, they are acquiring contracts that will be the first step to a long lasting presence in the US. Through networking as well as a series of events and conventions, Baverey hopes to build up INOVOTION’s customer base.
It’s a good start to the company’s mission of driving acceleration for cancer treatment research — not just in France, but worldwide.